KA
Kristin Abate
Chief Accounting Officer

Kristin Abate insider trades: Karyopharm Therapeutics (KPTI) stock sales

Chief Accounting Officer, Karyopharm Therapeutics Last trade Oct 16, 2026 13 Form 4 filings
$5K
Sold, last 12 months
6 sales
$0
Bought, last 12 months
0 buys
11
Open-market trades
since 2025
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Kristin reports to the SEC

Open-market buys and sales

11 trades reported on SEC Form 4, newest first

DateStockTypeValue
Oct 16, 2026KPTI↓ Sell$2K
Oct 1, 2026KPTI↓ Sell$450
Sep 1, 2026KPTI↓ Sell$38
May 14, 2026KPTI↓ Sell$504
Jan 28, 2026KPTI↓ Sell$352
Jan 21, 2026KPTI↓ Sell$2K
Oct 1, 2025KPTI↓ Sell$2K
Sep 15, 2025KPTI↓ Sell$148
Sep 3, 2025KPTI↓ Sell$81
Jul 22, 2025KPTI↓ Sell$952
Mar 4, 2025KPTI↓ Sell$4K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other KPTI insiders

Open-market trades in the last 12 months

About Kristin Abate's insider trades

Kristin Abate is Chief Accounting Officer at Karyopharm Therapeutics (KPTI). Since Mar 4, 2025, Kristin has reported no open-market purchases and 11 sales worth $12K on SEC Form 4. In the last 12 months: 6 sales ($5K).

Their filings also include grants and awards (5 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KPTI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.